Models and screening assays for drug discovery in osteoporosis

Expert Opinion on Drug Discovery

Volumn 5, Issue 12, 2010, Pages 1163-1174

  Rissanen, Jukka P ^a   Halleen, Jussi M ^a  

^a Pharmatest Services Ltd   (Finland)

Author keywords

animal models; bone cells; efficacy studies; osteoporosis; preclinical

Indexed keywords

GLUCOCORTICOID; PREDNISOLONE;

BONE CELL; BONE TURNOVER; CELL CULTURE; COCULTURE; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE MODEL; DRUG RESEARCH; EXPERIMENTAL MODEL; HUMAN; NONHUMAN; ORCHIECTOMY; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; REVIEW;

EID: 78649368289     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2010.532484     Document Type: Review

References (82)

1. Baron R. General principles of bone biology. In: Favus MJ, editor, Primer on the metabolic bone diseases and disorders of mineral metabolism. American Society for Bone and Mineral Research. Washington, DC, USA; 2003. p. 1-8
2. Consensus development conference. diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646-50
3. Prevention and management of osteoporosis. WHO Technical Report Series. Geneva, Switzerland: World Health Organization, 2003. Available from: http://whqlibdoc. who.int/trs/WHO-TRS-921.pdf
4. Dominguez LJ, Scalisi R, Barbagallo M. Therapeutic options in osteoporosis. Acta Biomed 2010;81(Suppl 1):55-65
5. Bonewald L. Osteocytes as multifunctional cells. J Musculoskelet Neuronal Interact 2006;6(4):331-3
6. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25(1):97-106
7. Cosman F. Treatment of osteoporosis and prevention of new fractures: role of intravenously administered bisphosphonates. Endocr Pract 2009;15(5):483-93
8. Staren ED, Omer S. Hormone replacement therapy in postmenopausal women. Am J Surg 2004;188(2):136-49
9. Silverman SL. New selective estrogen receptor modulators (SERMs) in development. Curr Osteoporos Rep 2010;8(3):151-3
10. Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 2005;5(6):618-25
11. Lewiecki EM. Denosumab-an emerging treatment for postmenopausal osteoporosis. Expert Opin Biol Ther 2010;10(3):467-76
12. Eriksen EF, Robins DA. Teriparatide: a bone formation treatment for osteoporosis. Drugs Today (Barc) 2004;40(11):935-48
13. Stroup J, Kane MP, Abu-Baker AM. Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm 2008;65(6):532-9
14. Bilezikian JP. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep 2008;6(1):24-30
15. Massey HM, Flanagan AM. Human osteoclasts derive from CD14-positive monocytes. Br J Haematol 1999;106(1):167-70
16. Pierelli L, Scambia G, d'Onofrio G, et al. Generation of multinuclear tartrate-resistant acid phosphatase positive osteoclasts in liquid culture of purified human peripheral blood CD34+ progenitors. Br J Haematol 1997;96:64-9
17. Sorensen MG, Henriksen K, Schaller S, et al. Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood. J Bone Miner Metab 2007;25(1):36-45
18. Rissanen JP, Ylipahkala H, Fagerlund KM, et al. Improved methods for testing antiresorptive compounds in human osteoclast cultures. J Bone Miner Metab 2009;27(1):105-9
19. Rissanen JP, Suutari S, Ylonen S, Halleen JM. Comparison of human and bovine bone substrates in human osteoclast cultures. J Bone Miner Res 2005;20(Suppl 1):abstract SU289
20. Boyde A, Ali NN, Jones SJ. Resorption of dentine by isolated osteoclasts in vitro. Br Dent J 1984;156:216-20
21. Chambers TJ, Revell PA, Fuller K, Athanasou NA. Resorption of bone by isolated rabbit osteoclasts. J Cell Sci 1984;66:383-99
22. Selander K, Lehenkari P, Vaananen HK. The effects of bisphosphonates on the resorption cycle of isolated osteoclasts. Calcif Tissue Int 1994;55:368-75
23. Bagger YZ, Foged NT, Andersen L, et al. CrossLaps for culture: an improved enzyme-linked immunosorbent assay (ELISA) for measuring bone resorption in vitro. J Bone Miner Res 1999;14(Suppl 1):abstract S370
24. Halleen JM, Tiitinen SL, Ylipahkala H, et al. Tartrate-resistant acid phosphatase 5b as a marker of bone resorption. Clin Lab 2006;52:499-509
25. Alatalo SL, Halleen JM, Hentunen TA, et al. Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium. Clin Chem 2000;46:1751-4
26. Kadis B, Goodson JM, Offenbacher S, et al. Characterization of osteoblast-like cells from fetal rat calvaria. J Dent Res 1980;59(11):2006-13
27. Qu Q, Perala-Heape M, Kapanen A, et al. Estrogen enhances differentiation of osteoblasts in mouse bone marrow culture. Bone 1998;22(3):201-9
28. Henrichsen E. Alkaline phosphatase in osteoblasts and fibroblasts cultivated in vitro. Exp Cell Res 1956;11(1):115-27
29. Bills CE, Eisenberg H, Pallante SL. Complexes of organic acids with calcium phosphate: the Von Kossa stain as a clue to the composition of bone mineral. Johns Hopkins Med J 1974;128(4):194-207
30. Rissanen JP, Suominen MI, Peng Z, et al. Short-term changes in serum PINP predict long-term changes in trabecular bone in the rat ovariectomy model. Calcif Tissue Int 2008;82:155-61
31. Broyles DL, Nielsen RG, Bussett EM, et al. Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase. Clin Chem 1998;44(10):2139-47
32. Melkko J, Kauppila S, Niemi S, et al. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 1996;42:947-54
33. Siggelkow H, Rebenstorff K, Kurre W, et al. Development of the osteoblast phenotype in primary human osteoblasts in culture: comparison with rat calvarial cells in osteoblast differentiation. J Cell Biochem 1999;75(1):22-35
34. Cough JE, Jones JR, Hench LL. Nodule formation and mineralisation of human primary osteoblasts cultured on a porous bioactive glass scaffold. Biomaterials 2004;25(11):2039-46
35. Sudo H, Kodama HA, Amagai Y, et al. In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J Cell Biol 1983;96(1):191-8
36. Murray E, Provvedini D, Curran D, et al. Characterization of a human osteoblastic osteosarcoma cell line (SAOS-2) with high bone alkaline phosphatase activity. J Bone Miner Res 1987;2(3):231-8
37. Yamashita T, Ishii H, Shimoda K, et al. Subcloning of three osteoblastic cell lines with distinct differentiation phenotypes from the mouse osteoblastic cell line KS-4. Bone 1996;19:429-36
38. Dang ZC, van Bezooijen RL, Karperien M, et al. Exposure of KS483 cells to estrogen enhances osteogenesis and inhibits adipogenesis. J Bone Miner Res 2002;17:394-404
39. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998;102(2):274-82
40. Bonewald LF. Osteocytes as dynamic multifunctional cells. Ann NY Acad Sci 2007;1116:281-90
41. Gu G, Hentunen TA, Nars M, et al. Estrogen protects primary osteocytes against glucocorticoid-induced apoptosis. Apoptosis 2005;10(3):583-95
42. Galli C, Passeri G, Macaluso GM. Osteocytes and WNT: the mechanical control of bone formation. J Dent Res 2010;89(4):331-43
43. Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 2010;87(2):99-107
44. Bonewald LF. Establishment and characterization of an osteocyte-like cell line, MLO-Y4. J Bone Miner Metab 1999;17(1):61-5
45. Boukhechba F, Balaguer T, Michiels JF, et al. Human primary osteocyte differentiation in a 3D culture system. J Bone Miner Res 2009;24(11):1927-35
46. Karsdal MA, Martin TJ, Bollerslev J, et al. Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res 2007;22(4):487-94
47. Karsdal MA, Neutzsky-Wulff AV, Dziegiel MH, et al. Osteoclasts secrete non-bone derived signals that induce bone formation. Biochem Biophys Res Commun 2008;366(2):483-8
48. Grano M, Colucci S, Cantatore FP, et al. Osteoclast bone resorption is enhanced in the presence of osteoblasts. Boll Soc Ital Biol Sper 1990;66(11):1051-7
49. Gurkan L, Ekeland A, Gautvik KM, et al. Bone changes after castration in rats. A model for osteoporosis. Acta Orthop Scand 1986;57:67-70
50. Kalu DN. The ovariectomized rat model of postmenopausal bone loss. Bone Miner 1991;15:175-91
51. Edwards MW, Bain SD, Bailey MC, et al. 17 beta estradiol stimulation of endosteal bone formation in the ovariectomized mouse: an animal model for the evaluation of bone-targeted estrogens. Bone 1992;13(1):29-34
52. Jerome CP, Lees CJ, Weaver DS. Development of osteopenia in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 1995;17(4 Suppl):403S-408S
53. Smith SY, Jolette J, Turner CH. Skeletal health: primate model of postmenopausal osteoporosis. Am J Primatol 2009;71(9):752-65
54. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res 1999;14:1614-21
55. Gerdhem P, Ivaska KK, Alatalo SL, et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 2004;19:386-93
56. Cremers S, Garnero P. Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls. Drugs 2006;66:2031-58
57. Henriksen K, Bohren KM, Bay-Jensen AC, Karsdal MA. Should biochemical markers of bone turnover be considered standard practice for safety pharmacology? Biomarkers 2010;15(3):195-204
58. Sorensen MG, Henriksen K, Schaller S, Karsdal MA. Biochemical markers in preclinical models of osteoporosis. Biomarkers 2007;12:266-86
59. Rissanen JP, Suominen MI, Peng Z, Halleen JM. Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Calcif Tissue Int 2008;82:108-15
60. Andersson N, Lindberg MK, Ohlsson C, et al. Repeated in vivo determinations of bone mineral density during parathyroid hormone treatment in ovariectomized mice. J Endocrinol 2001;170(3):529-37
61. Koivukangas A, Tuukkanen J, Hannuniemi R, et al. Effects of long-term administration of clodronate on growing rat bone. Calcif Tissue Int 2001;69(6):350-5
62. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 1987;2:595-610
63. Fox J, Miller MA, Newman MK, et al. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Calcif Tissue Int 2006;79(4):262-72
64. Bain SD, Jerome C, Shen V, et al. Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants. Osteoporos Int 2009;20(8):1417-28
65. Brommage R, Hotchkiss CE, Lees CJ, et al. Daily treatment with human recombinant parathyroid hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys. J Clin Endocrinol Metab 1999;84(10):3757-63
66. Smith SY, Recker RR, Hannan M, et al. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 2003;32(1):45-55
67. Vanderscueren D, Van Herck E, Suiker AM, et al. Bone and mineral metabolism in aged male rats: short and long term effects of androgen deficiency. Endocrinology 1992;130:2906-16
68. Erben RG, Eberle J, Stahr K, Goldberg M. Androgen deficiency induces high turnover osteopenia in aged male rats: a sequential histomorphometric study. J Bone Miner Res 2000;15:1085-98
69. Gao W, Reiser PJ, Coss CC, et al. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 2005;146(11):4887-97
70. Lane NE, Yao W. Glucocorticoid-induced bone fragility. Ann NY Acad Sci 2010;1192(1):81-3
71. Yao W, Cheng Z, Pham A, et al. Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum 2008;58(11):3485-97
72. Fleisch H, Russell RG, Simpson B, Muhlbauer RC. Prevention by a diphosphonate of immobilization "osteoporosis" in rats. Nature 1969;223(5202):211-12
73. Izawa Y, Makita T, Hino S, et al. Immobilization osteoporosis and active vitamin D: effect of active vitamin D analogs on the development of immobilization osteoporosis in rats. Calcif Tissue Int 1981;33(6):623-30
74. Peng Z, Tuukkanen J, Zhang H, et al. The mechanical strength of bone in different rat models of experimental osteoporosis. Bone 1994;15(5):523-32
75. Zhang R, Supowit SC, Klein GL, et al. Rat tail suspension reduces messenger RNA level for growth factors and osteopontin and decreases the osteoblastic differentiation of bone marrow stromal cells. J Bone Miner Res 1995;10(3):415-23
76. Grimston SK, Silva MJ, Civitelli R. Bone loss after temporarily induced muscle paralysis by Botox is not fully recovered after 12 weeks. Ann NY Acad Sci 2007;1116:444-60
77. Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 2009;122(2 Suppl):S33-45
78. Sellmeyer DE. Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA 2010;304(13):1480-4
79. Toulis KA, Anastasilakis AD. Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab. Osteoporos Int 2010;21(11):1963-4
80. Khosla S, Westendorf JJ, Oursler MJ. Building bone to reverse osteoporosis and repair fractures. J Clin Invest 2008;118(2):421-8
81. Musette P, Brandi ML, Cacoub P, et al. Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporos Int 2010;21(5):723-32
82. Kansara M, Tsang M, Kodjabachian L, et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 2009;119(4):837-51